Overview

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate next-day residual effects of MK-4305 on highway driving performance in healthy, non-elderly participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Suvorexant
Zopiclone